CannaPharmaRX, Inc.
CPMD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | -33.51% | -448.42% | -74.12% | -250.30% |
| EV / EBITDA | -2.50 | -9.30 | -3.38 | -3.81 |
| Quality | ||||
| ROIC | 62.72% | -202.12% | 203.66% | 76.61% |
| Gross Margin | -357.87% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.17 | -0.62 | 0.17 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 27.93% | -50.55% | 35.38% | -329.57% |
| Safety | ||||
| Net Debt / EBITDA | -1.84 | -8.94 | -2.96 | -3.44 |
| Interest Coverage | -1.59 | -0.93 | -2.28 | -1.99 |
| Efficiency | ||||
| Inventory Turnover | 3.77 | 0.06 | 4.30 | -8.11 |
| Cash Conversion Cycle | -359.05 | -24,835.84 | -8,482.83 | -79,561.77 |